Inex/Enzon Marqibo to ODAC
Executive Summary
FDA's Oncologic Drug Products Advisory Committee will review Inex/Enzon's liposomal vincristine formulation Marqibo (formerly Onco TCS) Dec. 1, firms announce. Sponsors seek third-line monotherapy indication for treatment of relapsed aggressive non-Hodgkin's lymphoma. FDA lists Dec. 1 and 2 as tentative ODAC meeting dates. [Editor's Note: For more information, visit 1FDAAdvisoryCommittee.com]...